Hamed Javan MD
Jewish General Hospital
Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.
Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer
Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.
EVEN MORE SEMINARS
Malcolm Wilson The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester
Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours
Dr Khurum Khan University College London Hospitals
Translational research in GI Oncology- how to make progress?
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer